President and CEO, 10% Owner of Catalyst Pharmaceutical Partners Inc. (CPRX, Financial) Patrick J Mcenany buys 5,000 shares of CPRX on 03/06/2009 at an average price of $1.55 a share.
CATALYST PHARMACEUTICAL PARTNERS INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending worldwide. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted `Fast Track` status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential Catalyst Pharmaceutical Partners Inc. has a market cap of $29.53 million; its shares were traded at around $1.25 .
Recent Trades of Catalyst Pharmaceutical Partners Inc. by CEO:
Recent Trades of Catalyst Pharmaceutical Partners Inc. by CFO:
Recent Trades of Catalyst Pharmaceutical Partners Inc. by Directors and Officers:
CATALYST PHARMACEUTICAL PARTNERS INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending worldwide. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted `Fast Track` status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential Catalyst Pharmaceutical Partners Inc. has a market cap of $29.53 million; its shares were traded at around $1.25 .
Recent Trades of Catalyst Pharmaceutical Partners Inc. by CEO:
- Buy: President and CEO, 10% Owner Patrick J Mcenany bought 5,000 shares of CPRX stock on 03/06/2009 at the average price of $1.55; the price of the stock has decreased by 19.35% since.
- Buy: President and CEO, Director, 10% Owner Patrick J Mcenany bought 2,500 more shares of CPRX stock on 12/17/2008 at the average price of $1.8; the price of the stock has decreased by 30.56% since.
Recent Trades of Catalyst Pharmaceutical Partners Inc. by CFO:
- Buy: V.P., Treasurer & CFO Jack Weinstein bought 100 shares of CPRX stock on 12/18/2008 at the average price of $2.24; the price of the stock has decreased by 44.2% since.
Recent Trades of Catalyst Pharmaceutical Partners Inc. by Directors and Officers:
- Buy: Director Philip H Coelho bought 1,000 shares of CPRX stock on 12/23/2008 at the average price of $1.6; the price of the stock has decreased by 21.88% since.
- Buy: Director, 10% Owner Hubert E Md Huckel bought 5,000 shares of CPRX stock on 12/19/2008 at the average price of $1.73; the price of the stock has decreased by 27.75% since.
- Buy: Director Philip H Coelho bought 1,500 shares of CPRX stock on 12/18/2008 at the average price of $2; the price of the stock has decreased by 37.5% since.
